News

ConfirmMDx is a laboratory-developed test (LDT), which assists urologists with identifying men who may safely forego unnecessary repeat biopsies. The prostate cancer assay can also identify an epigenetic

Under the drug discovery program, Vernalis will receive a payment of €0.5m from Servier on achieving the target. In addition, Vernalis will receive fees and a share in

Frontage will commence work on the analysis, formulation and validation of the various processes and procedures for manufacturing AHRO-001 in advance of the upcoming Phase I human clinical

Under the collaboration, Novo Nordisk will fund 10 Oxford researchers at the Kennedy Institute of Rheumatology to work within the partnership. A Joint steering committee with members from

The randomized, double-blind study will evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus. The clinical improvement at 24 weeks in an

The adverse events after intravenous administration of solutions containing particulates may include disruption of blood flow within small blood vessels in the lung, localized inflammation (swelling and redness),

The collaboration begins with a US co-promotion for AstraZeneca’s oral antiplatelet medicine BRILINTA, under which The Medicines Company sales force will begin supporting the product in May 2012.

The once-monthly erythropoiesis-stimulating agent (ESA) for anemia is co-marketed by Affymax and Takeda Pharmaceuticals USA (TPUSA) and distributed by TPUSA. Affymax chief executive officer John Orwin said, "Today’s

The Drug Controller General of India approved the new drug, indicated for relief from malaria-related symptoms, for marketing in India. Ranbaxy CEO and managing director Arun Sawhney said